On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval for POLIVY™ (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least 2 prior therapies.

POLIVY Access Solutions is your resource for access and reimbursement support after POLIVY is prescribed. We can help your patients and practice by providing:

·       Benefits investigations (BIs)

·       Prior authorization (PA) resources

·       Information about authorized specialty distributors

·       Sample billing and coding information

·       Resources for appeals

·       Referrals to co-pay support

·       Patient assistance options

A list of authorized specialty distributors is available at Genentech-Access.com/POLIVY

Resources:

Prescribing Information

Sample Coding Brochure